Opinion|Videos|December 9, 2025
Novel Pharmacotherapies and NCCN Guideline Recommendations
Explore the evolving landscape of desmoid tumor treatments, including chemotherapy, tyrosine kinase inhibitors, and emerging clinical trials.
Advertisement
Episodes in this series
Panelists discuss the questions below in this video.
- Up until a few years ago, there were no-FDA approved therapies for desmoid tumors. What was the role of chemotherapy and other pharmacotherapies like tyrosine kinase inhibitors in these patients? What is their role in current practice?
- What are the current NCCN guideline recommendations for treating desmoid tumors in patients?
- How do you utilize these in your daily practice?
- NCCN looks at surgery as a less preferred option vs. medication. How can this be incorporated into clinical practice, especially across specialties?
Advertisement
Related to this article
The Autus Size-Adjustable Valve, which can be expanded as children grow, may reduce the need for repeat open-heart surgeries for congenital defects.
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Although PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.
Invivyd's VYD2311 shows superior safety and tolerability vs Comirnaty in the phase 3 LIBERTY trial, with no vaccine interference.
Survodutide achieved up to 13.1% weight loss vs 3.1% with placebo at 76 weeks in adults with obesity and T2D in the phase 3 SYNCHRONIZE-2 trial.
A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.
Weekend catch-up sleep was associated with lower odds of overactive bladder and milder symptoms, with the benefit concentrated in the first 1.5 hours.
Advertisement
Advertisement
Trending on AJMC
1
Systemic Sclerosis Linked to Dramatic Rise in Lung Cancer Risk
2
FDA Approves First Heart Valve to Keep Pace With Children's Growth
3
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
4
Traditional Medicare OOP Cap Could Lower Costs, Raise Federal Spending
5